LINC01857 and central nervous system cancer: LINC01857 acts as an oncogene that promotes BC development by promoting H3K27Ac and CREB1 transcription [25], regulates glioma progression by modulating the miR-1281/TRIM65 pathway [26], promotes the proliferation of cancer cells by activating the PI3K/mTOR pathway, and facilitates the EMT process in DLBCL [26].